Molecular Partners is a clinical-stage biopharmaceutical company that specializes in the discovery, design, and development of a novel class of custom-built protein therapeutics known as DARPins (Designed Ankyrin Repeat Proteins). The company leverages its proprietary modular technology platform to create multi-specific and multi-functional drug candidates designed to address complex biological challenges in oncology, targeted radiotherapy, virology, and immunology. By engineering proteins with high stability, tunable half-lives, and precise multi-target binding capabilities, the enterprise collaborates with major global health partners to advance innovative treatments through preclinical and clinical evaluation phases.